Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 6.5% – Should You Sell?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) were down 6.5% on Friday . The company traded as low as $22.78 and last traded at $23.4450. Approximately 63,161 shares changed hands during trading, a decline of 82% from the average daily volume of 351,048 shares. The stock had previously closed at $25.08.

Pulse Biosciences News Roundup

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Business update highlighted strong clinical/operational results for the nPulse™ system — headline procedural success rates of 100% freedom from AF at 6 months and 96% procedural success in another cohort, which supports the commercial and clinical potential of the nanosecond PFA platform. Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
• Positive Sentiment: Pulse beat EPS expectations (reported loss of $0.26 vs. consensus -$0.32), which reduces near-term earnings risk relative to street estimates. Investors often view an EPS beat as supportive for sentiment. Pulse Biosciences Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Management will present at the 46th Annual TD Cowen Healthcare Conference — an opportunity to increase investor visibility, refresh guidance/roadmap, and potentially catalyze interest if management provides positive commercialization updates. Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
• Neutral Sentiment: Full Q4 earnings call transcripts and reconstructions are available (Seeking Alpha, MSN); useful for investors who want management’s tone on commercialization timelines, reimbursement, and cash runway but no new headline news. Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analyst/market previews (e.g., Benzinga) discuss earnings potential and longer-term opportunity; these are background context rather than immediate catalysts. A Glimpse of Pulse Biosciences’s Earnings Potential
• Negative Sentiment: Revenue materially missed expectations — reported essentially flat/negative revenue versus street estimates (company reported minimal revenue vs. expected ~$0.23M), which likely drove near-term selling pressure despite the EPS beat. Pulse Biosciences Earnings & Press Release Summary
• Negative Sentiment: Insider stock sales disclosed in two filings (~$470.6k and ~$472.6k) — significant insider selling can be interpreted negatively by the market and may amplify downward pressure. Pulse Biosciences (NASDAQ:PLSE) Insider Sells $470,600.00 in Stock Pulse Biosciences (NASDAQ:PLSE) Insider Sells $472,600.00 in Stock

Analyst Upgrades and Downgrades

PLSE has been the subject of a number of recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 price target on shares of Pulse Biosciences in a research note on Friday. Mizuho set a $30.00 target price on Pulse Biosciences in a research note on Friday, February 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Stock Performance

The firm has a market capitalization of $1.52 billion, a P/E ratio of -19.81 and a beta of 1.77. The stock’s 50 day simple moving average is $16.21 and its 200 day simple moving average is $16.03.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. The firm had revenue of ($0.09) million during the quarter, compared to analysts’ expectations of $0.23 million.

Insider Activity

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $23.53, for a total transaction of $470,600.00. Following the transaction, the insider owned 43,298 shares in the company, valued at approximately $1,018,801.94. This trade represents a 31.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 80,000 shares of company stock worth $1,876,200. 74.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its holdings in shares of Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the period. Alliancebernstein L.P. raised its stake in Pulse Biosciences by 6.7% in the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after buying an additional 1,300 shares in the last quarter. Westside Investment Management Inc. lifted its holdings in Pulse Biosciences by 2.9% during the fourth quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock worth $911,000 after buying an additional 1,886 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after acquiring an additional 2,156 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.